

Ref. No:- NIDL/BSE/2020-21/17

Dated: October 3, 2020

To,
Corporate Services Department,
BSE Limited, P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.
BSE Scrip Code: NIDL 540204

Sub: Outcome of the Board Meeting

Dear Sir/Madam,

With reference to the above subject matter, we wish to inform you that the Board of Directors of the Company at their meeting held Saturday October 3, 2020 at registered office 1, Matru Chaya, karve Road, Opp. of Dr. Bedekar Hospital, Naupada (Thane), of the company have inter alia approved the following:

A. Change in the Main Object clause in Memorandum of Association as per the Companies Act, 2013 as follows:

- 1. "To carry on the business of manufacturing, processing, formulating, producing, refining, fermenting, converting, distilling, purifying, blending, buying, importing, stocking, supplying, selling, distributing, trading, exporting and dealing in all kinds and varieties of chemicals of various specifications, purities, nature including speciality chemicals, organic and inorganic chemicals and compounds thereof, bio-chemicals, petro-chemicals, insecticides, cleaning chemicals, chemical compounds, laboratory chemicals, scientific chemicals, agricultural chemicals, preservative chemicals, industrial chemicals, heavy chemicals, pharmaceutical chemicals, fine chemicals, photographic chemicals, water purification chemicals and all or any of the by-product resulted there from, whether used presently or to be invented in future, for industrial, medical, pharmaceutical, agricultural, domestic, household, waste treatment purposes."*
- 2. "To manufacture, produce, refine, process, formulate, buy, sell, export, import or otherwise deal in all types of heavy and light chemicals, chemical elements and compounds, laboratory and scientific chemicals, pharmaceutical chemicals, agricultural chemicals, hexamine, fertilizers, petro-chemicals, industrial chemicals or any mixtures, derivatives, articles and compounds thereof, acids, gases, and compounds, dyes, cosmetics, drugs, Perfumery, pharmaceutical and medical preparations."*

B. Change the name of the Company from “Narendra investments (Delhi) Limited” to a suitable name pursuant to the change of main object:

Pursuant to the Regulation 45 (1)(b) of the SEBI LODR, the Company will change its name to align with the proposed change in the main object of the company, when at least fifty per cent of the total revenue in the preceding one year has been accounted for by the new proposed object clause.

C. Alteration of MOA and AOA:

With reference to the above proposal, pursuant to the change of main object of the company and change of name of the company to adopt suitable modifications/alterations to give the effect to the MOA and AOA of the Company.

D. Acquisition of suitable business assets/ manufacturing facilities to fulfill the proposed main object of the company

Company will explore all possible options to secure suitable manufacturing facility / facilities by way of acquisition and/or by leasing to achieve the above proposed object of the Company.

E. To hire and/ or get associated with the professional team having expert knowledge in the new field or in the proposed main object of the company

F. Board has considered disinvestment of subsidiaries by way of sale of shares

The outcome of this Board Meeting is also available on the Company's website at www.narendrainvestment.com and on the website of the Stock Exchange at www.bseindia.com.

Please take the same on your records.

Thanking you.

Yours Sincerely,
For **Narendra Investments (Delhi) Limited**

Laxmikant Kabra
(Director)
DIN: 00061346